Hereditary breast-ovarian cancer team of the University Medical Centre Groningen (UMCG) - A report

[1] Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., Easton D.F., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected

[2] King M.C., Marks J.H., Mandell J.B., Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, pp. 643-646, (2003)

[3] Stirling D., Evans D.G., Pichert G., Shenton A., Kirk E.N., Rimmer S., Steel C.M., Lawson S., Busby-Earle R.M., Walker J., Lalloo F.I., Eccles D.M., Lucassen A.M., Porteous M.E., Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system, J Clin Oncol, 23, pp. 5588-5596, (2005)

[4] Vasen H.F., Tesfay E., Boonstra H., Mourits M.J., Rutgers E., Verheyen R., Oosterwijk J., Beex L., Early detection of breast and ovarian cancer in families with BRCA mutations, Eur J Cancer, 41, 4, pp. 549-554, (2005)

[5] Roosmalen M.S., Verhoef L.C., Stalmeier P.F., Hoogerbrugge N., Van Daal W.A., Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy, J Clin Oncol, 20, pp. 2092-2100, (2002)

[6] Zweemer R.P., Van Diest P.J., Verheijen R.H., Ryan A., Gille J.J., Sijmons R.H., Jacobs I.J., Menko F.H., Kenemans P., Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations, Gynecol Oncol, 76, pp. 45-50, (2000)

[7] Alvarado-Cabrero I., Young R.H., Vamvakas E.C., Scully R.E., Carcinoma of the fallopian tube: A clinicopathological study of 105 cases with observations on staging and prognostic factors, Gynecol Oncol, 72, pp. 367-379, (1999)

[8] Lundstrom E., Christow A., Kersemaekers W., Svane G., Azavedo E., Soderqvist G., Mol-Arts M., Barkfeldt J., Von Schoultz B., Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density, Am J Obstet Gynecol, 186, pp. 717-722, (2002)

[9] Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., Lavasseur B.I., Barton D.L., Novotny P.J., Dakhil S.R., Rodger K., Rummans T.A., Christensen B.J., Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial, Lancet, 356, pp. 2059-2063, (2000)

[1] Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., Easton D.F., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected

[2] King M.C., Marks J.H., Mandell J.B., Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, pp. 643-646, (2003)

[3] Stirling D., Evans D.G., Pichert G., Shenton A., Kirk E.N., Rimmer S., Steel C.M., Lawson S., Busby-Earle R.M., Walker J., Lalloo F.I., Eccles D.M., Lucassen A.M., Porteous M.E., Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system, J Clin Oncol, 23, pp. 5588-5596, (2005)

[4] Vasen H.F., Tesfay E., Boonstra H., Mourits M.J., Rutgers E., Verheyen R., Oosterwijk J., Beex L., Early detection of breast and ovarian cancer in families with BRCA mutations, Eur J Cancer, 41, 4, pp. 549-554, (2005)

[5] Roosmalen M.S., Verhoef L.C., Stalmeier P.F., Hoogerbrugge N., Van Daal W.A., Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy, J Clin Oncol, 20, pp. 2092-2100, (2002)

[6] Zweemer R.P., Van Diest P.J., Verheijen R.H., Ryan A., Gille J.J., Sijmons R.H., Jacobs I.J., Menko F.H., Kenemans P., Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations, Gynecol Oncol, 76, pp. 45-50, (2000)

[7] Alvarado-Cabrero I., Young R.H., Vamvakas E.C., Scully R.E., Carcinoma of the fallopian tube: A clinicopathological study of 105 cases with observations on staging and prognostic factors, Gynecol Oncol, 72, pp. 367-379, (1999)

[8] Lundstrom E., Christow A., Kersemaekers W., Svane G., Azavedo E., Soderqvist G., Mol-Arts M., Barkfeldt J., Von Schoultz B., Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density, Am J Obstet Gynecol, 186, pp. 717-722, (2002)

[9] Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., Lavasseur B.I., Barton D.L., Novotny P.J., Dakhil S.R., Rodger K., Rummans T.A., Christensen B.J., Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial, Lancet, 356, pp. 2059-2063, (2000)